MA49617A - Analogues d'egf(a), préparation, formulations et utilisations associées - Google Patents

Analogues d'egf(a), préparation, formulations et utilisations associées

Info

Publication number
MA49617A
MA49617A MA049617A MA49617A MA49617A MA 49617 A MA49617 A MA 49617A MA 049617 A MA049617 A MA 049617A MA 49617 A MA49617 A MA 49617A MA 49617 A MA49617 A MA 49617A
Authority
MA
Morocco
Prior art keywords
egf
analogues
formulations
preparation
related uses
Prior art date
Application number
MA049617A
Other languages
English (en)
Inventor
Kim Vilbour Andersen
Florian Dismer
Jesper F Lau
Bhavesh Premdjee
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA49617A publication Critical patent/MA49617A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA049617A 2017-07-19 2018-07-19 Analogues d'egf(a), préparation, formulations et utilisations associées MA49617A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17182011 2017-07-19

Publications (1)

Publication Number Publication Date
MA49617A true MA49617A (fr) 2020-05-27

Family

ID=59383424

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049617A MA49617A (fr) 2017-07-19 2018-07-19 Analogues d'egf(a), préparation, formulations et utilisations associées

Country Status (6)

Country Link
US (1) US20200165313A1 (fr)
EP (1) EP3655426A1 (fr)
JP (1) JP2020527159A (fr)
CN (1) CN111164098A (fr)
MA (1) MA49617A (fr)
WO (1) WO2019016300A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3402811T1 (sl) 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti
CA3068956A1 (fr) 2017-07-19 2019-01-24 Novo Nordisk A/S Composes bifonctionnels
AU2020326265A1 (en) 2019-08-07 2022-02-03 Novo Nordisk A/S Solid compositions comprising an EGF(A) derivative and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2025056575A1 (fr) 2023-09-11 2025-03-20 Novo Nordisk A/S Anticorps anti-domaine il-6

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
DE60038097T2 (de) 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
CA2572770A1 (fr) 2004-07-08 2006-01-19 Novo-Nordisk A/S Marquages de prolongation de polypeptide
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
ES2401965T3 (es) 2009-02-19 2013-04-25 Novo Nordisk A/S Modificación de Factor VIII
WO2012177741A1 (fr) 2011-06-20 2012-12-27 Genentech, Inc. Polypeptides liant pcsk9 et leurs procédés d'utilisation
CN105722526B (zh) 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
SI3402811T1 (sl) * 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti

Also Published As

Publication number Publication date
EP3655426A1 (fr) 2020-05-27
CN111164098A (zh) 2020-05-15
WO2019016300A1 (fr) 2019-01-24
US20200165313A1 (en) 2020-05-28
JP2020527159A (ja) 2020-09-03

Similar Documents

Publication Publication Date Title
IL288423A (en) Cannabinoid formulations
EP3732185A4 (fr) Conjugués et préparation et utilisation associées
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA51287A (fr) Analogues d'incrétine et leurs utilisations
SG10201808151RA (en) Cortistatin analogues and syntheses and uses thereof
EP3359241A4 (fr) Formulations d'analogues de pthrp, timbres transdermiques de celles-ci, et utilisations de celles-ci
ZA202109070B (en) Imatinib formulations, manufacture, and uses thereof
MA49617A (fr) Analogues d'egf(a), préparation, formulations et utilisations associées
EP3880828A4 (fr) Vecteurs végétaux, compositions et utilisations associées
SI3927315T1 (sl) Okusne formulacije
SG11202102383VA (en) Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3347006A4 (fr) Analogues deutérés d'étifoxine, leurs dérivés et leurs utilisations
EP3411121A4 (fr) Conjugués glucose de triptolide, analogues et utilisations correspondants
EP4058568A4 (fr) Vecteurs végétaux, compositions et utilisations associées
EP3436434A4 (fr) Analogues d'indoline et leurs utilisations
MX372702B (es) Una composicion antimicrobiana.
MA50047A (fr) Administration orale d'analogues peptidiques de glp-1
IN2014KO00357A (fr)
IL269305A (en) Cannabinoid formulations and dosage
EP3401685A4 (fr) Agent diagnostique et médicament comprenant adamts13 comme ingrédient principal
EP3723836A4 (fr) Dispositif d'administration intranasale
DK3911298T3 (da) Formuleringer
PH12018501758A1 (en) Oritavancin formulations
EP3585438A4 (fr) Conjugués d'androstènedione chimioluminescents
EP3634507C0 (fr) Plates-formes d'administration de médicament prolongée par voie orale